Leflunomide Orion

Leflunomide, the active ingredient in Leflunomide Orion, is a Disease-modifying antirheumatic drug (DMARD) presented as an oral tablet for oral use. It treats rheumatoid arthritis and psoriatic arthritis in adult patients.\n\nGNH India supplies Leflunomide Orion as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease-modifying antirheumatic drug used in inflammatory joint disorders.\n\n- Rheumatoid arthritis: reduces disease activity and slows structural joint damage.\n- Psoriatic arthritis: improves joint pain, swelling and skin manifestations.\n- Moderate to severe rheumatoid arthritis: helps achieve clinical remission and functional improvement.

Leflunomide may cause a range of adverse reactions, from mild to severe.\n\nCommon Side Effects:\n- Diarrhea: mild to moderate gastrointestinal upset.\n- Elevated liver enzymes: transient increases in ALT/AST.\n- Hypertension: new‑onset or worsening blood pressure.\n- Rash: non‑specific skin eruptions.\n- Headache: occasional tension‑type headaches.\n\nSerious or Rare Side Effects:\n- Hepatotoxicity: severe liver injury or failure.\n- Bone marrow suppression: leukopenia, anemia or thrombocytopenia.\n- Severe infections: opportunistic or bacterial infections requiring hospitalization.\n- Pulmonary toxicity: interstitial lung disease or pneumonitis.

Before initiating therapy, several safety considerations are required.\n\n- Pregnancy: contraindicated (Category X); effective contraception must be used.\n- Liver function: obtain baseline tests and monitor regularly.\n- Blood pressure: check and control hypertension prior to treatment.\n- Infections: screen for active infections and postpone therapy if present.\n- Hematology: perform baseline complete blood count and repeat periodically.\n- Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Leflunomide can interact with several medicines, affecting efficacy or safety.\n\nMajor Interactions (Avoid):\n- Warfarin: increased anticoagulant effect and bleeding risk.\n- Live vaccines: risk of uncontrolled infection due to immunosuppression.\n- Methotrexate: additive hepatotoxicity; concurrent use requires close monitoring.\n\nModerate Interactions (Monitor Closely):\n- Antihypertensives: leflunomide may reduce blood‑pressure‑lowering effect.\n- CYP1A2 inhibitors (e.g., fluconazole): raise leflunomide plasma concentrations.\n- Statins: combined use may increase risk of myopathy.